BioMall
Brand Store/BDB Bioscience/BD HorizonTM R718 Mouse Anti-Mouse SLAMF9
BD HorizonTM R718 Mouse Anti-Mouse SLAMF9
GENERAL CATALOGUE

BD HorizonTM R718 Mouse Anti-Mouse SLAMF9

569819 · 0.1 mg

BDB Bioscience · Cat: 569819

₹240 – ₹370 approx.This price excludes freight and taxes. Please RFQ to get the final price.

Reach 3+ verified distributors

Catalog No: 569819
Category: reagents
Pack Size: 0.1 mg
Brand: BDB Bioscience

Description

Multicolor flow cytometric analysis of SLAMF9 expression by Mouse splenic plasmacytoid dendritic cells. C57BL/6 Mouse splenocytes were treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes, washed, and preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody Mouse BD Fc Block Cat. No. 553141/553142 . The cells were then stained with FITC Hamster Anti-Mouse CD3e Cat. No. 553062 , FITC Rat Anti-Mouse CD19 Cat. No. 553785 , BUV395 Rat Anti-Mouse CD45R/B220 Cat. No. 563793 , BD Horizon BV421 Rat Anti-Mouse CD317 BST2 Cat. No. 566431 antibodies, and with either BD Horizon R718 Mouse IgG1, kappa Isotype Control Cat. No. 567470; Left Plot or BD Horizon R718 Mouse Anti-Mouse SLAMF9 antibody Cat. No. 569819/569894; Right Plot at 0.5 mug/test. BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The pseudocolor density plot showing the correlated expression of SLAMF9 or Ig Isotype control staining versus CD317 BST2 was derived by progressive gating on B220/CD45R+ Lineage-negative cells CD3e-CD19- with the forward and side light-scatter characteristics of viable 7-AAD-negative splenic leukocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. Data shown on this Technical Data Sheet are not lot specific. Multicolor flow cytometric analysis of SLAMF9 expression by Mouse splenic plasmacytoid dendritic cells. C57BL/6 Mouse splenocytes were treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes, washed, and preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody Mouse BD Fc Block Cat. No. 553141/553142 . The cells were then stained with FITC Hamster Anti-Mouse CD3e Cat. No. 553062 , FITC Rat Anti-Mouse CD19 Cat. No. 553785 , BUV395 Rat Anti-Mouse CD45R/B220 Cat. No. 563793 , BD Horizon BV421 Rat Anti-Mouse CD317 BST2 Cat. No. 566431 antibodies, and with either BD Horizon R718 Mouse IgG1, kappa Isotype Control Cat. No. 567470; Left Plot or BD Horizon R718 Mouse Anti-Mouse SLAMF9 antibody Cat. No. 569819/569894; Right Plot at 0.5 mug/test. BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The pseudocolor density plot showing the correlated expression of SLAMF9 or Ig Isotype control staining versus CD317 BST2 was derived by progressive gating on B220/CD45R+ Lineage-negative cells CD3e-CD19- with the forward and side light-scatter characteristics of viable 7-AAD-negative splenic leukocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. Data shown on this Technical Data Sheet are not lot specific. Multicolor flow cytometric analysis of SLAMF9 expression by Mouse splenic plasmacytoid dendritic cells. C57BL/6 Mouse splenocytes were treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes, washed, and preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody Mouse BD Fc Block Cat. No. 553141/553142 . The cells were then stained with FITC Hamster Anti-Mouse CD3e Cat. No. 553062 , FITC Rat Anti-Mouse CD19 Cat. No. 553785 , BUV395 Rat Anti-Mouse CD45R/B220 Cat. No. 563793 , BD Horizon BV421 Rat Anti-Mouse CD317 BST2 Cat. No. 566431 antibodies, and with either BD Horizon R718 Mouse IgG1, kappa Isotype Control Cat. No. 567470; Left Plot or BD Horizon R718 Mouse Anti-Mouse SLAMF9 antibody Cat. No. 569819/569894; Right Plot at 0.5 mug/test. BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The pseudocolor density plot showing the correlated expression of SLAMF9 or Ig Isotype control staining versus CD317 BST2 was derived by progressive gating on B220/CD45R+ Lineage-negative cells CD3e-CD19- with the forward and side light-scatter characteristics of viable 7-AAD-negative splenic leukocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. Data shown on this Technical Data Sheet are not lot specific. Show More Multicolor flow cytometric analysis of SLAMF9 expression by Mouse splenic plasmacytoid dendritic cells. C57BL/6 Mouse splenocytes were treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes, washed, and preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody Mouse BD Fc Block Cat. No. 553141/553142 . The cells were then stained with FITC Hamster Anti-Mouse CD3e Cat. No. 553062 , FITC Rat Anti-Mouse CD19 Cat. No. 553785 , BUV395 Rat Anti-Mouse CD45R/B220 Cat. No. 563793 , BD Horizon BV421 Rat Anti-Mouse CD317 BST2 Cat. No. 566431 antibodies, and with either BD Horizon R718 Mouse IgG1, kappa Isotype Control Cat. No. 567470; Left Plot or BD Horizon R718 Mouse Anti-Mouse SLAMF9 antibody Cat. No. 569819/569894; Right Plot at 0.5 mug/test. BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The pseudocolor density plot showing the correlated expression of SLAMF9 or Ig Isotype control staining versus CD317 BST2 was derived by progressive gating on B220/CD45R+ Lineage-negative cells CD3e-CD19- with the forward and side light-scatter characteristics of viable 7-AAD-negative splenic leukocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. Data shown on this Technical Data Sheet are not lot specific. Show More Multicolor flow cytometric analysis of SLAMF9 expression by Mouse splenic plasmacytoid dendritic cells. C57BL/6 Mouse splenocytes were treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes, washed, and preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody Mouse BD Fc Block Cat. No. 553141/553142 . The cells were then stained with FITC Hamster Anti-Mouse CD3e Cat. No. 553062 , FITC Rat Anti-Mouse CD19 Cat. No. 553785 , BUV395 Rat Anti-Mouse CD45R/B220 Cat. No. 563793 , BD Horizon BV421 Rat Anti-Mouse CD317 BST2 Cat. No. 566431 antibodies, and with either BD Horizon R718 Mouse IgG1, kappa Isotype Control Cat. No. 567470; Left Plot or BD Horizon R718 Mouse Anti-Mouse SLAMF9 antibody Cat. No. 569819/569894; Right Plot at 0.5 mug/test. BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The pseudocolor density plot showing the correlated expression of SLAMF9 or Ig Isotype control staining versus CD317 BST2 was derived by progressive gating on B220/CD45R+ Lineage-negative cells CD3e-CD19- with the forward and side light-scatter characteristics of viable 7-AAD-negative splenic leukocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. Data shown on this Technical Data Sheet are not lot specific. Multicolor flow cytometric analysis of SLAMF9 expression by Mouse splenic plasmacytoid dendritic cells. C57BL/6 Mouse splenocytes were treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes, washed, and preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody Mouse BD Fc Block Cat. No. 553141/553142 . The cells were then stained with FITC Hamster Anti-Mouse CD3e Cat. No. 553062 , FITC Rat Anti-Mouse CD19 Cat. No. 553785 , BUV395 Rat Anti-Mouse CD45R/B220 Cat. No. 563793 , BD Horizon BV421 Rat Anti-Mouse CD317 BST2 Cat. No. 566431 antibodies, and with either BD Horizon R718 Mouse IgG1, kappa Isotype Control Cat. No. 567470; Left Plot or BD Horizon R718 Mouse Anti-Mouse SLAMF9 antibody Cat. No. 569819/569894; Right Plot at 0.5 mug/test. BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. The pseudocolor density plot showing the correlated expression of SLAMF9 or Ig Isotype control staining versus CD317 BST2 was derived by progressive gating on B220/CD45R+ Lineage-negative cells CD3e-CD19- with the forward and side light-scatter characteristics of viable 7-AAD-negative splenic leukocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. Data shown on this Technical Data Sheet are not lot specific.

More from BDB Bioscience

BD HorizonTM BV421 Mouse Anti-Human TIGIT
BD HorizonTM BV421 Mouse Anti-Human TIGIT
570445
reagents
BD OptiBuildTM BV750 Mouse Anti-Human HLA-DQ
BD OptiBuildTM BV750 Mouse Anti-Human HLA-DQ
746968
reagents
BD OptiBuildTM BV750 Rat Anti-Mouse CD93 (Early B Lineage)
BD OptiBuildTM BV750 Rat Anti-Mouse CD93 (Early B Lineage)
746849
reagents
BD OptiBuildTM BV510 Rat Anti-Mouse Delta-Like Protein 1
BD OptiBuildTM BV510 Rat Anti-Mouse Delta-Like Protein 1
744997
reagents
BD OptiBuildTM BUV805 Mouse Anti-Human CD275
BD OptiBuildTM BUV805 Mouse Anti-Human CD275
748933
reagents
BD OptiBuildTM BV650 Rat Anti-Mouse CD23
BD OptiBuildTM BV650 Rat Anti-Mouse CD23
740456
reagents
BD OptiBuildTM R718 Rat Anti-Mouse CCRL2
BD OptiBuildTM R718 Rat Anti-Mouse CCRL2
752021
reagents
BD PharmingenTM Mouse B Lymphocyte Activation Antibody Cocktail, with Isotype Control; PE-CyTM7 CD25, PE CD69, & FITC CD19
BD PharmingenTM Mouse B Lymphocyte Activation Antibody Cocktail, with Isotype Control; PE-CyTM7 CD25, PE CD69, & FITC CD19
558064
reagents